4-[2-(4-硝基苯氧基)乙基]吗啉 | 65321-29-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-[2-(4-硝基苯氧基)乙基]吗啉
• 中文别名: 3-吡啶-叔丁基酮
• 英文名称: 1-(pyridin-3-yl)-2,2-dimethylpropanone
• 英文别名: 2,2-dimethyl-1-(pyridin-3-yl)propanone；3-tert-butylcarbonylpyridine；2,2-Dimethyl-1-(3-pyridyl)-propanon；2,2-dimethyl-1-(pyridin-3-yl)propan-1-one；3-pivaloylpyridine；2,2-dimethyl-1-pyridin-3-ylpropan-1-one
• CAS: 65321-29-1
• 化学式: C₁₀H₁₃NO
• 分子量: 163.219
• InChiKey: DSIWVPPBVHNWQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-[2-(4-硝基苯氧基)乙基]吗啉 在 sodium hydroxide 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 反应 1.08h， 生成 3-t-butyl-7,7a-dihydro-7-methyl-1-tosyl-1H-pyrazolo<3,4-b>pyridine
  参考文献：
  名称：

  Street, Jonathan D.; Baradarani, M. Mehdi; Beddoes, Roy L., Journal of Chemical Research, Miniprint, 1987, # 5, p. 1247 - 1285

  摘要：

  DOI：
• 作为产物：
  描述：

  3-吡啶甲醛 在 Jones-reagent 作用下， 以 乙醚 、 丙酮 为溶剂， 反应 2.0h， 生成 4-[2-(4-硝基苯氧基)乙基]吗啉
  参考文献：
  名称：

  Fungizide Pyridinderivate I: α-Trichlormethyl-3-pyridinmethanole

  摘要：

  DOI：

  10.1007/bf00810286

文献信息

• COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS
  申请人：Kandula Mahesh

  公开号：US20150133407A1

  公开（公告）日：2015-05-14

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of viscid or excessive mucus, cough, inflammation, redness in sore throat, infection in the throat, sore throat, abnormal mucus secretion, impaired mucus transport, allergic rhinitis, asthma, COPD, respiratory muscular disorders and pain in acute sore throat.

  本发明涉及公式I的化合物或其药用可接受的盐，以及它们的聚合物、溶剂化物、对映体、立体异构体和水合物。包含有效量的公式I化合物的药物组合物，以及用于治疗呼吸系统疾病的方法，可以口服、颊部、直肠、局部、经皮、经粘膜、静脉、非肠道给药、糖浆或注射剂的形式制备。此类组合物可用于治疗粘性或过量粘液、咳嗽、喉咙痛的红肿、喉咙感染、喉咙痛、异常粘液分泌、粘液运输受损、过敏性鼻炎、哮喘、慢性阻塞性肺病（COPD）、呼吸肌疾病和急性喉咙痛的疼痛。
• MODULATORS OF THE RELAXIN RECEPTOR 1
  申请人：The United States of America, as Represented by the Secretary, Dept. of Health & Human Services

  公开号：US20150119426A1

  公开（公告）日：2015-04-30

  Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R 1 , and R 2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.

  本文揭示了人类松弛素受体1的调节剂，例如，公式（I）中的A、R1和R2如本文所定义，这些调节剂在治疗哺乳动物松弛素受体1介导的人类健康方面，例如心血管疾病中是有用的。还公开了一种包含药用适宜载体和本公开的至少一种化合物的组合物，以及一种用于治疗介导人类松弛素受体1的哺乳动物健康方面的干预方法。
• <i>N</i>-Heterocyclic Carbene-Catalyzed Decarboxylative Alkylation of Aldehydes
  作者：Takuya Ishii、Yuki Kakeno、Kazunori Nagao、Hirohisa Ohmiya

  DOI：10.1021/jacs.9b00880

  日期：2019.3.6

  N-heterocyclic carbene catalysis promoted the unprecedented decarboxylative coupling of aryl aldehydes and tertiary or secondary alkyl carboxylic acid-derived redox-active esters to produce aryl alkyl ketones. The mild and transition-metal-free reaction conditions are attractive features of this method. The power of this protocol was demonstrated by the functionalization of pharmaceutical drugs and natural

  我们发现 N-杂环卡宾催化促进了芳醛和叔或仲烷基羧酸衍生的氧化还原活性酯的前所未有的脱羧偶联，以生产芳烷基酮。温和且不含过渡金属的反应条件是该方法的吸引人的特征。药物和天然产物的功能化证明了该协议的力量。提出了一种反应途径，包括从 Breslow 中间体的烯醇化物形式到氧化还原酯的单电子转移，然后再结合所得自由基对以形成碳-碳键。
• PYRROLIDINYL SULFONE RORGAMMA MODULATORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20150191483A1

  公开（公告）日：2015-07-09

  Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

  描述了公式（I）的RORγ调节剂，或其立体异构体、互变异构体、药物可接受的盐、溶剂化物或前药，其中所有取代基都在此定义。还提供了包含相同成分的药物组合物。这类化合物和组合物在调节细胞中RORγ活性的方法和治疗受疾病或紊乱困扰的主体中是有用的，例如，主体将从调节RORγ活性中获益的自免疫和/或炎症紊乱。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERIODONTITIS AND RHEUMATOID ARTHRITIS
  申请人：Kandula Mahesh

  公开号：US20150133475A1

  公开（公告）日：2015-05-14

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of periodontitis and rheumatoid arthritis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

  该发明涉及公式I的化合物或其药用可接受的盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括公式I化合物的有效量的药物组合物，以及用于牙周炎和类风湿关节炎治疗的方法可以制成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道、糖浆或注射剂的制剂。